Up to now, there has been limited research concerning the effect of Bevacizumab on sepsis, and only a few studies have investigated the role of Bevacizumab as a therapeutic opportunity targeting VEGF molecules that are critical in the pathogenesis of sepsis. This evidence concerns the gene VEGFA and Sepsis.